vs
BRIGHT HORIZONS FAMILY SOLUTIONS INC.（BFAM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BRIGHT HORIZONS FAMILY SOLUTIONS INC.的1.1倍（$772.1M vs $733.7M），BRIGHT HORIZONS FAMILY SOLUTIONS INC.同比增速更快（8.8% vs 5.9%），BRIGHT HORIZONS FAMILY SOLUTIONS INC.自由现金流更多（$258.5M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 8.5%）
Bright Horizons Family Solutions总部位于美国马萨诸塞州牛顿市，是美国规模最大的雇主赞助育儿服务运营商，除核心育儿服务外，还提供备用育儿、老人照护、学费项目管理、教育咨询、学生贷款偿还方案等多元服务，覆盖企业员工福利及教育支持领域。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BFAM vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.1倍
$733.7M
营收增速更快
BFAM
高出3.0%
5.9%
自由现金流更多
BFAM
多$96.8M
$161.8M
两年增速更快
RVTY
近两年复合增速
8.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $733.7M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | 19.3% | — |
| 营业利润率 | 6.2% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | 8.8% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $0.38 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BFAMRVTY
| Q4 25 | $733.7M | $772.1M | ||
| Q3 25 | $802.8M | $698.9M | ||
| Q2 25 | $731.6M | $720.3M | ||
| Q1 25 | $665.5M | $664.8M | ||
| Q4 24 | $674.1M | $729.4M | ||
| Q3 24 | $719.1M | $684.0M | ||
| Q2 24 | $670.1M | $691.7M | ||
| Q1 24 | $622.7M | $649.9M |
净利润BFAMRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $78.6M | $46.7M | ||
| Q2 25 | $54.8M | $53.9M | ||
| Q1 25 | $38.0M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $54.9M | $94.4M | ||
| Q2 24 | $39.2M | $55.4M | ||
| Q1 24 | $17.0M | $26.0M |
毛利率BFAMRVTY
| Q4 25 | 19.3% | — | ||
| Q3 25 | 27.0% | 53.6% | ||
| Q2 25 | 25.0% | 54.5% | ||
| Q1 25 | 23.4% | 56.5% | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 25.2% | 56.3% | ||
| Q2 24 | 24.2% | 55.7% | ||
| Q1 24 | 21.7% | 54.6% |
营业利润率BFAMRVTY
| Q4 25 | 6.2% | 14.5% | ||
| Q3 25 | 15.1% | 11.7% | ||
| Q2 25 | 11.8% | 12.6% | ||
| Q1 25 | 9.4% | 10.9% | ||
| Q4 24 | 7.2% | 16.3% | ||
| Q3 24 | 12.4% | 14.3% | ||
| Q2 24 | 10.3% | 12.4% | ||
| Q1 24 | 6.4% | 6.8% |
净利率BFAMRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | 9.8% | 6.7% | ||
| Q2 25 | 7.5% | 7.5% | ||
| Q1 25 | 5.7% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | 7.6% | 13.8% | ||
| Q2 24 | 5.8% | 8.0% | ||
| Q1 24 | 2.7% | 4.0% |
每股收益（稀释后）BFAMRVTY
| Q4 25 | $0.38 | $0.86 | ||
| Q3 25 | $1.37 | $0.40 | ||
| Q2 25 | $0.95 | $0.46 | ||
| Q1 25 | $0.66 | $0.35 | ||
| Q4 24 | $0.50 | $0.77 | ||
| Q3 24 | $0.94 | $0.77 | ||
| Q2 24 | $0.67 | $0.45 | ||
| Q1 24 | $0.29 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $140.1M | $919.9M |
| 总债务越低越好 | $747.6M | — |
| 股东权益账面价值 | $1.3B | $7.3B |
| 总资产 | $3.9B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.56× | — |
8季度趋势，按日历期对齐
现金及短期投资BFAMRVTY
| Q4 25 | $140.1M | $919.9M | ||
| Q3 25 | $116.6M | $931.4M | ||
| Q2 25 | $179.2M | $991.8M | ||
| Q1 25 | $112.0M | $1.1B | ||
| Q4 24 | $110.3M | $1.2B | ||
| Q3 24 | $109.9M | $1.2B | ||
| Q2 24 | $140.2M | $2.0B | ||
| Q1 24 | $63.7M | $1.7B |
总债务BFAMRVTY
| Q4 25 | $747.6M | — | ||
| Q3 25 | $747.5M | — | ||
| Q2 25 | $797.0M | — | ||
| Q1 25 | $872.7M | — | ||
| Q4 24 | $918.4M | — | ||
| Q3 24 | $925.7M | — | ||
| Q2 24 | $931.9M | — | ||
| Q1 24 | $938.1M | — |
股东权益BFAMRVTY
| Q4 25 | $1.3B | $7.3B | ||
| Q3 25 | $1.4B | $7.4B | ||
| Q2 25 | $1.4B | $7.6B | ||
| Q1 25 | $1.3B | $7.6B | ||
| Q4 24 | $1.3B | $7.7B | ||
| Q3 24 | $1.4B | $7.9B | ||
| Q2 24 | $1.3B | $7.9B | ||
| Q1 24 | $1.2B | $7.8B |
总资产BFAMRVTY
| Q4 25 | $3.9B | $12.2B | ||
| Q3 25 | $3.9B | $12.1B | ||
| Q2 25 | $3.9B | $12.4B | ||
| Q1 25 | $3.8B | $12.4B | ||
| Q4 24 | $3.9B | $12.4B | ||
| Q3 24 | $3.9B | $12.8B | ||
| Q2 24 | $3.8B | $13.4B | ||
| Q1 24 | $3.8B | $13.4B |
负债/权益比BFAMRVTY
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.57× | — | ||
| Q1 25 | 0.66× | — | ||
| Q4 24 | 0.72× | — | ||
| Q3 24 | 0.66× | — | ||
| Q2 24 | 0.73× | — | ||
| Q1 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $350.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $258.5M | $161.8M |
| 自由现金流率自由现金流/营收 | 35.2% | 21.0% |
| 资本支出强度资本支出/营收 | 12.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $402.4M | $509.4M |
8季度趋势，按日历期对齐
经营现金流BFAMRVTY
| Q4 25 | $350.7M | $182.0M | ||
| Q3 25 | $-17.6M | $138.5M | ||
| Q2 25 | $134.2M | $134.3M | ||
| Q1 25 | $86.2M | $128.2M | ||
| Q4 24 | $337.5M | $174.2M | ||
| Q3 24 | $-8.9M | $147.9M | ||
| Q2 24 | $109.4M | $158.6M | ||
| Q1 24 | $116.3M | $147.6M |
自由现金流BFAMRVTY
| Q4 25 | $258.5M | $161.8M | ||
| Q3 25 | $-42.4M | $120.0M | ||
| Q2 25 | $115.4M | $115.5M | ||
| Q1 25 | $70.9M | $112.2M | ||
| Q4 24 | $240.2M | $149.8M | ||
| Q3 24 | $-32.2M | $125.6M | ||
| Q2 24 | $86.8M | $136.6M | ||
| Q1 24 | $96.9M | $129.7M |
自由现金流率BFAMRVTY
| Q4 25 | 35.2% | 21.0% | ||
| Q3 25 | -5.3% | 17.2% | ||
| Q2 25 | 15.8% | 16.0% | ||
| Q1 25 | 10.7% | 16.9% | ||
| Q4 24 | 35.6% | 20.5% | ||
| Q3 24 | -4.5% | 18.4% | ||
| Q2 24 | 13.0% | 19.7% | ||
| Q1 24 | 15.6% | 20.0% |
资本支出强度BFAMRVTY
| Q4 25 | 12.6% | 2.6% | ||
| Q3 25 | 3.1% | 2.6% | ||
| Q2 25 | 2.6% | 2.6% | ||
| Q1 25 | 2.3% | 2.4% | ||
| Q4 24 | 14.4% | 3.4% | ||
| Q3 24 | 3.2% | 3.3% | ||
| Q2 24 | 3.4% | 3.2% | ||
| Q1 24 | 3.1% | 2.7% |
现金转化率BFAMRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | -0.22× | 2.97× | ||
| Q2 25 | 2.45× | 2.49× | ||
| Q1 25 | 2.26× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | -0.16× | 1.57× | ||
| Q2 24 | 2.79× | 2.87× | ||
| Q1 24 | 6.85× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BFAM
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
